Mainz Biomed N.V (NASDAQ:MYNZ)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 0.32. At the close of trading, the stock’s price was $7.41, to imply an increase of 2.21% or $0.16 in intraday trading. The MYNZ share’s 52-week high remains $48.80, putting it -558.57% down since that peak but still an impressive 50.74% since price per share fell to its 52-week low of $3.65. The company has a valuation of $16.47M, with an average of 0.34 million shares in intraday trading volume over the past 10 days and average of 175.94K shares over the past 3 months.

Mainz Biomed N.V (NASDAQ:MYNZ) trade information

After registering a 2.21% upside in the last session, Mainz Biomed N.V (MYNZ) has traded red over the past five days. The 5-day price performance for the stock is 21.67%, and 58.67% over 30 days. With these gigs, the year-to-date price performance is 71.53%. Short interest in Mainz Biomed N.V (NASDAQ:MYNZ) saw shorts transact 41306.0 shares and set a 0.3 days time to cover.

Mainz Biomed N.V (MYNZ) estimates and forecasts

The rating firms project that company’s revenue will grow 19.60% compared to the previous financial year.

MYNZ Dividends

Mainz Biomed N.V has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

The next major institution holding the largest number of shares is VONTOBEL HOLDING LTD. with 25000.0 shares, or about 0.1181% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $10025.0.

Going by data provided on Nov 30, 2024 , Fidelity NASDAQ Composite Index Fund holds roughly 9.01 shares. This is just over 0.45% of the total shares, with a market valuation of $66778.0